Ron M. Philip
Independent DirectorMr. Ron M. Philip is Independent Director of Avalo Therapeutics, Inc. from June 23, 2026. Mr. Philip is Member of Advisory Board at Parallel Biosystems, Inc. from June 2026. He is Independent Director of City Therapeutics, Inc. since July 2024. Mr. Philip is Executive Chair of CREATE Medicines, Inc since May 2026. He served as President and Chief Executive Officer of Orbital Therapeutics, which was acquired by Bristol Myers Squibb. Mr. Philip also serves on the boards of City Therapeutics and Harmony Biosciences (NASDAQ: HRMY) and advises several private biotechnology companies. A proven leader in biopharma and biotech, Mr. Philip has extensive experience in building high-growth organizations, driving strategic transformation and advancing novel therapies from discovery through commercialization. Prior to Orbital, Mr. Philip held successive leadership roles at Spark Therapeutics, culminating in his appointment as Chief Executive Officer. In these roles, he led the launch of LUXTURNA®, the first FDA approved gene therapy for a genetic disease, helped position company for its acquisition by the Roche Group and guided Spark’s evolution from a founder led startup to a fully integrated gene therapy company within Roche. In his career, Mr. Philip spent a decade at Pfizer and Wyeth, holding senior global leadership roles including Regional President for Africa and the Middle East, Head of Global Business Unit Strategy, Head of Business Development Search & Evaluation and Commercial Development Lead for Pfizer’s Innovative Products division. He began his career at Deloitte Consulting and Merck & Co. Beyond his corporate leadership roles, Mr. Philip is an active contributor to the life sciences and Philadelphia communities. He has served on the boards of the Chamber of Commerce for Greater Philadelphia, Life Sciences Pennsylvania, the Academy of Natural Sciences of Drexel University and Cure Duchenne. Mr. Philip earned his degree from Drexel University.
Positions
- Company NameCity Therapeutics, Inc.Stock CodeCTYPositionIndependent Director
